Latest Breaking News On - Platform identifies proprietary - Page 1 : comparemela.com

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNasdaq stock marketCompany nasdaqExchange commissionCantor fitzgerald coAlaunos therapeutics incCompany library phaseAlaunos therapeutics inc statement of operationsLibrary phaseAlaunos therapeutics inc selected balance sheet dataNational cancer instituteDevelopment expensesCantor fitzgeraldSleeping beautyPlatform identifies proprietaryQuarter ended september

Alaunos Therapeutics (TCRT) Reports Q3, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Alaunos Therapeutics (TCRT) Reports Q3, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Alaunos therapeutics inc selected balance sheet dataNational cancer instituteDevelopment expensesAlaunos therapeutics incCantor fitzgerald coNasdaq stock marketAlaunos therapeutics inc statement of operationsLibrary phaseCompany nasdaqCompany library phaseExchange commissionAlaunos therapeuticsCantor fitzgeraldSleeping beautyPlatform identifies proprietaryQuarter ended september

Alaunos Therapeutics Announces Third Quarter 2023 Financial

TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy.

United statesNational cancer instituteCompany nasdaqLibrary phaseNasdaq stock marketAlaunos therapeutics incCompany library phaseDevelopment expensesCantor fitzgerald coExchange commissionCantor fitzgeraldSleeping beautyPlatform identifies proprietaryQuarter ended septemberSolasia licenseCollaboration agreement

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHeather andersonKevins boyleDown library phaseCompany library phaseAlaunos therapeutics inc statement of operationsLibrary phaseAlaunos therapeutics incCantor fitzgerald coRestructuring organizationDevelopment expensesCompany nasdaqNasdaq stock marketAlaunos therapeutics inc selected balance sheet dataExchange commissionSleeping beauty

Alaunos Therapeutics (TCRT) to wind down its TCR-T Library Phase 1/2 trial and prioritize the hunTR platform

Alaunos Therapeutics (TCRT) to wind down its TCR-T Library Phase 1/2 trial and prioritize the hunTR platform
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Kevins boyleLibrary phaseAlaunos therapeutics incCantor fitzgerald coDevelopment expensesRestructuring organizationDown library phaseCompany library phaseCompany nasdaqAlaunos therapeuticsSleeping beautyChief executive officerClinical dataPlatform identifies proprietaryWinding downCantor fitzgerald